Brought to you by 
Barr buys Duramed
21 Feb 2002
Executive Summary
Specialty generics and proprietary pharmaceuticals company Barr Laboratories has agreed to buy women's health care pharmaceutical specialist Duramed Pharmaceuticals in a stock swap. Barr says it will issue approximately 8.25mm of its common shares, worth $588.5mm (based on Barr's average trading price). Duramed stockowners get one Barr share for every 3.9 Duramed common held.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com